Compare CFFN & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFN | URGN |
|---|---|---|
| Founded | 1893 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 977.3M | 922.1M |
| IPO Year | 2010 | 2016 |
| Metric | CFFN | URGN |
|---|---|---|
| Price | $6.93 | $18.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $7.25 | ★ $29.29 |
| AVG Volume (30 Days) | 783.0K | ★ 816.7K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | ★ 4.91% | N/A |
| EPS Growth | ★ 79.31 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $16,300,000.00 | $1,128,000.00 |
| Revenue This Year | $20.16 | $119.37 |
| Revenue Next Year | $6.62 | $64.79 |
| P/E Ratio | $43.31 | ★ N/A |
| Revenue Growth | ★ 6.54 | N/A |
| 52 Week Low | $4.90 | $3.42 |
| 52 Week High | $7.84 | $30.00 |
| Indicator | CFFN | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 42.20 |
| Support Level | $6.08 | $18.55 |
| Resistance Level | $7.31 | $20.44 |
| Average True Range (ATR) | 0.18 | 1.40 |
| MACD | -0.05 | -0.15 |
| Stochastic Oscillator | 27.59 | 23.84 |
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.